US Edition
Hallucinogen DMT an Effective Antidepressant in Small Clinical Trial
- A Nature Medicine paper published on Monday by Erritzoe and colleagues reported that a single intravenous DMT dose rapidly reduced depressive symptoms in 34 adults with major depressive disorder.
- Many people with major depressive disorder do not respond adequately to selective serotonin reuptake inhibitors or tolerate side effects, while dimethyltryptamine's brief intravenous effects could enable shorter therapy sessions.
- The randomized design assigned 17 people to each arm, administering intravenous infusions over about 10 minutes, and by two weeks DMT recipients showed greater depression score reductions with 47% meeting remission by three months.
- In terms of safety, researchers reported side-effect rates of 64.7% and 62.5% with DMT versus 23.5% placebo, noting study limitations including small sample and 88.2% white participants.
- Regulatory reviews and larger phase 3 trials will determine clinical adoption, with Erritzoe's team testing HLP004 and others like AtaiBeckley and 5‑MeO‑DMT advancing in parallel.
28 Articles
28 Articles
Short-duration psychedelic therapy shows promise for major depression treatment
A phase IIa randomized trial found that intravenous dimethyltryptamine (DMT) with structured psychological support produced rapid reductions in depressive symptoms in adults with major depressive disorder. Improvements were statistically significant versus placebo at two weeks, with mostly mild-to-moderate adverse events and the need for larger confirmatory studies emphasized.
Major depressive disorder is one of the leading causes of disability worldwide
Major depression is one of the main causes of disability in the world and, despite advances in psychopharmaceuticals and psychotherapy, a significant part of patients do not respond to conventional treatments.In this context, the search for innovative alternatives has led to research on psychedelic substances, such as dimethyltryptamine (DMT), present in ayahuasca, a traditional Amazonian drink.A clinical trial, published this week in the presti…
Preliminary, the results add to a growing body of evidence that psychedelic drugs, when combined with psychotherapy, can help alleviate depression in millions of people worldwide.
Coverage Details
Bias Distribution
- 54% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
